Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial

BACKGROUND: Preoperative capecitabine-based chemoradiotherapy (CRT) is feasible for the treatment of resectable locally advanced rectal cancer (LARC). To try to improve efficacy, we conducted a phase II study in which the epidermal growth factor receptor-targeting monoclonal antibody cetuximab was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Velenik, Vaneja, Ocvirk, Janja, Oblak, Irena, Anderluh, Franc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472951/
https://www.ncbi.nlm.nih.gov/pubmed/23077464
http://dx.doi.org/10.2478/v10019-012-0030-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472951/
https://www.ncbi.nlm.nih.gov/pubmed/23077464
http://dx.doi.org/10.2478/v10019-012-0030-2

Ejemplares similares